About CHV
CHV is a venture capital firm founded in 2008. It is primarily based out of Braintree, United States. As of Jul 2026, CHV has invested in 21 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series B round of Epitel Overall, CHV portfolio has seen 2 IPOs and 5 acquisitions including key companies like Novozymes, Sera Prognostics and Maxwell Health. A lot of funds co-invest with CHV, with names like AMED Ventures sharing a substantial percentage of its portfolio. CHV has team of 12 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 2 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
CHV's List of Top Investments
CHV has a portfolio of 21 companies. Their most notable investments are in Rejoni and PanTher Therapeutics.Their portfolio spans across United States, Canada and Denmark. They have invested in Life Sciences, Enterprise Applications, High Tech and 5 other sectors, across stages such as Series A, Series B and 2 more. Here is the list of top investments by CHV:1. Novozymes
Developer of biosolutions and enzymes for multiple industries and applications of biotechnology. It offers biosolutions using biotechnology, enzymes, microorganisms, and precision proteins to create sustainable products.The firm develops natural oral health treatments that affect the oral microbiota by using probiotics, enzymes, and bioactive to deliver solutions for human health. The firm provides Ronozyme feed enzymes that strengthen animal husbandry development.
Key facts about Novozymes
Transforming cardiac rhythm management with innovative extravascular pacing and defibrillation solutions. This medical device company is dedicated to designing novel extravascular leads and deployment systems, aiming to eliminate the risks and drawbacks of traditional transvenous leads. They focus on both pacing and defibrillation solutions, offering a new option for pacing without entering the heart and life-saving ICD benefits without transvenous leads. Their extravascular solutions place leads outside the vasculature and heart, maintaining the integrity of the heart while delivering much-needed therapy. They are developing the EV Temporary Pacing Lead System and the EV-ICD Lead System, both designed to address pacing and defibrillation needs without entering the heart or vascular system. This innovative approach seeks to reduce complications associated with transvenous leads and improve patient outcomes in cardiac rhythm management. They are focused on medical devices, electrophysiology, cardiology, temporary pacing, extracardiac, and extravascular solutions.
Key facts about AtaCor Medical
- Founded Year: 2014
- Location: San Clemente (United States)
- Stage: Series D
- Total Funding till date: $137M
- Investors: aMoon, Broadview Ventures and 7 Others
- Latest Funding Round: Series D, Oct 06, 2025, $*****
- Highlight: Editors' Pick
3. Rejoni
Developer of therapeutics to treat women health conditions. The company is working on a soft gel-like material, called Juveena Hydrogel to prevent intrauterine adhesions after uterine surgery.
Key facts about Rejoni
- Founded Year: 2020
- Location: Bedford (United States)
- Stage: Series B
- Total Funding till date: $66.3M
- Employee Count: 21 as on Aug 31, 2026
- Investors: Delos Capital, Ascension Ventures and 8 Others
- Latest Funding Round: Series B, Jun 16, 2026, $*****
- Highlight: Editors' Pick
4. Epitel
Provider of a wearable EEG recording system for epilepsy monitoring and control. It offers a scalp wearable medical-grade seizure monitoring system. The rechargeable device can be applied to the scalp by an adhesive and can be worn irrespective of time and location. The device is paired via Bluetooth with a mobile application that detects and records seizures. The obtained data can be then used by a doctor to optimize one's treatment and lifestyle.
Key facts about Epitel
- Founded Year: 2007
- Location: Salt Lake City (United States)
- Stage: Series B
- Total Funding till date: $38.5M
- Employee Count: 62 as on Aug 31, 2026
- Investors: Genoa Ventures, Wavemaker 360 and 8 Others
- Latest Funding Round: Series B, Jul 28, 2026, $*****
- Highlight: Editors' Pick
Innovating stroke prevention with minimally invasive Left Atrial Appendage Occlusion. This company focuses on addressing the clinical need for improved stroke prevention in patients with Atrial Fibrillation (Afib). The company is developing a system for Left Atrial Appendage Occlusion (LAAO) as an alternative to blood thinners, aiming to reduce stroke risk without increased bleeding risk. Their solution targets a single-operator, same-day procedure performed under conscious sedation, eliminating the need for transesophageal echocardiography (TEE). This medical device company is dedicated to transforming LAAO procedures, offering a minimally invasive solution for stroke prevention. They are committed to advancing patient care through innovative medical technology.
Key facts about Conformal Medical
- Founded Year: 2016
- Location: Nashua (United States)
- Stage: Series D
- Total Funding till date: $161M
- Employee Count: 55 as on Aug 31, 2026
- Investors: Fidelity Investments, Catalyst Health Ventures and 4 Others
- Latest Funding Round: Series D, Jul 31, 2025, $*****
- Highlight: Editors' Pick
CHV's Year-on-Year Investment Trends
CHV has invested in 21 companies over the last 18 years, with an average of 1 new investment annually in the last 10 years. In 2025, it made 2 investments, while as of Jul 2026, it has made 2 investments in this year. Its most recent first time investment was in Lena and most recent follow-on round was in Epitel.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 2 | 2 |
2025 | 2 | 0 | 2 |
2024 | 1 | 2 | 3 |
2023 | 1 | 1 | 2 |
2022 | 2 | 0 | 2 |
2021 | 1 | 0 | 1 |
2020 | 2 | 2 | 4 |
2019 | 0 | 0 | 0 |
2018 | 1 | 0 | 1 |
CHV's Investments by Stage
CHV has made 9 investments in Series A stage with an average round size of $9.88M, 5 investments in Series B stage with an average round size of $23.1M, 3 investments in Seed stage with an average round size of $1.12M and 1 investment in Series C stage with an average round size of $15M.Stage of entry | No. of Investments |
|---|---|
Series A | 9 |
Series B | 5 |
Seed | 3 |
Series C | 1 |
Note: We have considered here, only first round of investments
CHV's Investments by Sector
CHV has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Healthcare, Enterprise Applications and High Tech. Notably, it has invested in 18 Tech companies, 17 Enterprise (B2B) companies, 10 Tech hardware companies and at least 4 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 13 |
HealthTech | 3 |
Healthcare | 3 |
Enterprise Applications | 2 |
High Tech | 2 |
Others | 6 |
Note: We have considered here, only first round of investments
CHV's Investments by Geography
CHV has made most investments in United States (18).CHV's recent investments
CHV has made 2 investments in 2026 so far - Epitel and Rejoni.Here are the most recent investments by CHV:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 28, 2026 | United States | Series B | 3423 | ||
Jun 16, 2026 | United States | Series B | 8037 | [+6] | |
Apr 22, 2025 | United States | Seed | 4767 | [+3] | |
Feb 19, 2025 | United States | Series A | 9104 | ||
Aug 02, 2024 | United States | Series B | 9296 | [+4] |
IPOs and Publicly Listed companies in CHV's Portfolio
2 of CHV's portfolio companies have become public. Sera Prognostics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Nov 2018 and GI Dynamics got listed on the Australian Securities Exchange (ASX) at marketcap of $65.6M.Here are CHV's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 29, 2018 | Jan 04, 2011 | Series A | 1183 | |
Jul 09, 2011 | Dec 2008 | Series C | 1641 |
Acquired companies in CHV's Portfolio
5 companies from CHV's portfolio have been acquired. The most recent acquisition was Novozymes in Dec 2023 by Kerry for $*****.Here are CHV's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 12, 2023 | - | - | 8976 | |
Jun 04, 2018 | Dec 17, 2013 | Series A | 5137 | |
Apr 16, 2018 | Apr 24, 2013 | Series A | 6055 | |
Sep 04, 2014 | Mar 07, 2008 | Series A | 8297 | |
Mar 01, 2011 | Dec 16, 2009 | Seed | 3465 |
Team profile of CHV
CHV has a team of 12 members including 1 Partner and 1 Venture Partner located in United States. CHV's team does not sit on the board of any company as of now.Co-investors of CHV
Over the past 18 years, 107 investors have co-invested in CHV's portfolio companies. This includes only funds.
- Invested before CHV: Broadview Ventures, aMoon and 28 others have invested in rounds before CHV. There is 1 company where Broadview Ventures has invested before CHV and 1 company where aMoon has invested before CHV.
- Top Co-investors of CHV: 42 investors entered a company along with CHV. These include investors like AMED Ventures (2 companies).
- Invested after CHV: A total of 35 investors have invested in CHV's portfolio after their investments. Top Investors include Arboretum Ventures (2 companies), BayMed Venture Partners (1 company) and Clavystbio (1 company).
Recent News related to CHV
•
Rejoni, Inc. Secures $25 Million in Financing for Juveena® Hydrogel SystemThe Joplin Globe•Jun 16, 2026•Rejoni, Iyengar Capital Partners, Clavystbio, AMED Ventures and 5 others
•
Esperto Medical Announces Completion of Oversubscribed Series A Financingintelligence360•Mar 03, 2025•Esperto Medical, CHV, Bold Capital Partners, Wavemaker 360 and 3 others
•
Venova Medical Announces $30 Million Series B Financing and Appointment of New Board MemberPRWeb•Sep 04, 2024•Venova Medical, CHV, ShangBay Capital, Mirae Asset Capital Markets and 3 others
•
Brixton Biosciences Raises $33M in Series B FundingFinSMEs•May 14, 2024•Brixton Biosciences, Schooner Capital, SV Health Investors, Excelestar Ventures and 3 others
•
AtaCor Medical closes $28 million Series C financingG-MedTech•Apr 25, 2024•AtaCor Medical, Arboretum Ventures, Broadview Ventures, Hatteras Venture Partners and 2 others
•
Avive Solutions Raises $56.5M FundingSilicon Valley Journals•Apr 18, 2024•Avive, Questa Capital, Laerdal Million Lives Fund, CHV and 2 others
•
Instylla Closes $30M Equity FinancingFinSMEs•Aug 16, 2023•Instylla, Delos Capital, Excelestar Ventures, Ascension Ventures and 4 others
•
Rejoni Closes $25M Series B FinancingFinSMEs•Dec 08, 2022•CHV, Ascension Ventures, Rejoni, Delos Capital and 4 others
•
Avive Solutions raises $22M for wirelessly connected AED technologyMassDevice•Mar 16, 2022•Avive, Questa Capital, CHV, Laerdal Million Lives Fund
•
Epitel Secures $12.5 Million Series A Financing for Wearable, Wireless EEG Monitoring SystemBusiness Wire•Feb 16, 2022•Epitel, CHV, Genoa Ventures, Dexcom and 6 others
